My Screeners
No screeners
System Screeners
My Watchlists
No watchlists
System Watchlists
Loading...
CollPlant Biotechnologies is a regenerative and aesthetic medicine company that produces recombinant human Type I collagen (rhCollagen) using a proprietary plant-based genetic engineering platform. The company's core business is centered on developing and commercializing medical aesthetics and 3D bioprinting technologies, particularly bioink products for print-based creation of tissues and organs, as well as aesthetic dermal and soft tissue filler products. Its revenue sources include sales of bioinks for 3D bioprinting, rhCollagen for aesthetic treatments, and rhCollagen-based products targeting tendinopathy and wound healing.
Secondary product lines include commercially available rhCollagen-based bioink platforms named Collink.3D 50, Collink.3D 90, and Collink.3D 50L, designed for different mechanical properties and tissue types. The company also develops a photocurable regenerative dermal filler aimed at skin rejuvenation, lifting, and facial contouring in cooperation with AbbVie, and 3D-bioprinted breast implants intended for tissue regeneration rather than permanent synthetic or silicone-based implants. Additionally, it markets products in Europe such as VergenixSTR, a soft tissue matrix for tendinopathy, and VergenixFG, a flowable rhCollagen-based gel for treatment of deep surgical incisions and wounds.
CollPlant operates primarily from Rehovot, Israel, with a wholly-owned subsidiary, CollPlant Ltd., owning its intellectual property and another subsidiary, CollPlant Inc., established in the United States though not operational as of its latest filings. Its products are being developed and commercialized globally, including in the United States, Canada, Europe, and Israel. The company generates revenue both through sales of its own products and through collaborations with other medical and biotech companies. Additionally, its business model entails ongoing research and development investment, with currently negative cash flows and net losses, and a reliance on additional financing and milestone agreements to support its operations until profitability.
Click to see warnings
Effective scoring profile: Standard company
Remaining score inputs are provider supplied.
Log in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see financial data
Log in for full accessIt is important that you understand how Findx arrives at Fair Value. Please take a minute to watch this short explainer.
It is very important that you understand this
Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.